Skip to main content

Table 1 The principal characteristics and further details of eligible articles

From: The impact of anti-tumor approaches on the outcomes of cancer patients with COVID-19: a meta-analysis based on 52 cohorts incorporating 9231 participants

Author Year Study design Region Number of patient Male Median age (IQR) (years) Diagnosis method for COVID-19 Cancer type Comparison group
Kuderer NM [6] 2020 Retro-prospective multi-national 928 468 66 (57–76) RT-PCR non-specific cancer patients with no treatment
Lee LYW [19] 2020 Prospective UK 800 449 69 (59–76) RT-PCR non-specific cancer patients with no treatment
Zhang L [14] 2020 Retrospective China 28 17 65 (56–70) RT-PCR solid tumor cancer patients with no treatment
Stroppa EM [20] 2020 Retrospective Italy 25 20 71 (mean) (50–84) RT-PCR non-specific cancer patients with no treatment
Yang K [7] 2020 Retrospective China 205 96 63 (56–70) RT-PCR non-specific cancer patients with no treatment
Zhang H [21] 2020 Retrospective China 107 60 66 (36–98) RT-PCR and/or radiology non-specific cancer patients with no treatment
Robilotti EV [22] 2020 Retrospective USA 423 212 NA RT-PCR non-specific cancer patients with no treatment
Yarza R [23] 2020 Prospective Spain 63 34 NA RT-PCR and/or radiology solid tumor cancer patients treated other options
Li Q [24] 2020 Retrospective China 59 31 63 (54–70) RT-PCR non-specific cancer patients with no treatment
Jee J [25] 2020 Retrospective USA 309 159 NA RT-PCR non-specific cancer patients with no treatment
Sanchez-Pina JM [26] 2020 Retrospective Spain 39 23 64 (mean) RT-PCR hematological malignancies cancer patients with no treatment
Pinato DJ [15] 2020 Retrospective multi-national 890 503 68 (mean) RT-PCR non-specific cancer patients with no treatment
Assaad S [27] 2020 Retrospective France 55 26 64 (mean) RT-PCR non-specific cancer patients with no treatment
Garassino MC [28] 2020 Retrospective multi-national 200 141 68 (61–75) RT-PCR Thoracic Cancer cancer patients with no treatment
Liang WH [29] 2020 Retrospective China 18 12 60 (47–87) RT-PCR non-specific cancer patients with no treatment
Ma J [30] 2020 Retrospective China 37 20 62 (IQR: 59–70) RT-PCR and/or antibody test solid tumor cancer patients with no treatment
Mehta V [11] 2020 Retrospective USA 218 127 69 (10–92) RT-PCR non-specific cancer patients with no treatment
Yu J [31] 2020 Retrospective China 12 10 66 (48–78) RT-PCR and/or CT solid tumor cancer patients with no active antitumor treatment
Tian J [4] 2020 Retrospective China 232 119 64 (58–69) RT-PCR non-specific cancer patients with surgery
Fox TA [32] 2020 Retrospective UK 55 38 63 (23–88) RT-PCR, CT, and clinical features hematological malignancies cancer patients with no treatment
Booth S [33] 2020 Prospective UK 66 41 73 (IQR: 63–81) RT-PCR, radiological, and clinical features hematological malignancies cancer patients with no treatment
Cattaneo C [34] 2020 Retrospective Italy 102 66 68 (mean) RT-PCR hematological malignancies cancer patients with no treatment
Lara OD [35] 2020 Retrospective USA 121 NA 64 (IQR: 51–73) RT-PCR and CT gynecologic cancer cancer patients with no treatment
Liu C [36] 2020 Retrospective China 216 113 63 (IQR: 57–70) RT-PCR solid tumor cancer patients with no treatment
Luo J [37] 2020 Retrospective USA 102 49 68 (IQR: 61–75) RT-PCR lung cancer cancer patients with no treatment
Mato AR [38] 2020 Retrospective multi-national 198 125 63 (35–92) RT-PCR chronic lymphocytic leukemia cancer patients with no treatment
Rogado J [39] 2020 Retrospective Spain 45 30 71 (34–90) RT-PCR non-specific cancer patients with no treatment
Russell B [40] 2020 Retro-prospective UK 156 90 65 (mean) RT-PCR solid tumor cancer patients with no treatment
Scarfò L [41] 2020 Retrospective multi-national 190 126 72 (48–94) RT-PCR chronic lymphocytic leukemia cancer patients with no treatment
Vuagnat P [42] 2020 Retrospective France 58 NA 58 (IQR:48–68) RT-PCR and/or CT breast cancer cancer patients with no treatment
Wang BO [43] 2020 Retrospective USA 58 30 67 RT-PCR multiple myeloma cancer patients with no treatment
Wang J [44] 2020 Retrospective China 283 141 63 (IQR: 55–70) RT-PCR non-specific cancer patients with no treatment
Gonzalez-cao M [45] 2020 Retrospective Spain 50 27 69 (6–94) clinical or RT-PCR melanoma cancer patients with no treatment
De Melo AC [46] 2020 Retrospective Brazil 181 71 55 (2–88) RT-PCR non-specific cancer patients with no active antitumor treatment
Albiges L [47] 2020 Retrospective France 178 76 61 (52–71) RT-PCR and/or CT non-specific cancer patients with no treatment
Martínez-López J [48] 2020 Retrospective Spain 167 95 71 (IQR: 62–78) RT-PCR multiple myeloma (MM) cancer patients with no treatment
Martín-Moro F [49] 2020 Retrospective Spain 34 19 72.5 (35–94) RT-PCR and/or CT hematological malignancies cancer patients with no treatment
Lattenist R [50] 2021 Retrospective Belgium 13 10 70 (IQR: 59–79) RT-PCR and/or CT hematological malignancies cancer patients with no treatment
Nakamura S [51] 2020 Retrospective Japan 32 22 74.5 (24–90) RT-PCR non-specific cancer patients with no treatment
Rogiers A [52] 2021 Retrospective multi-national 110 72 63 (27–86) RT-PCR non-specific cancer patients with no treatment
Glenthøj A [16] 2021 Prospective Denmark 66 40 66.7 (25–91)   hematological malignancies cancer patients with no treatment
Song C [17] 2020 Retrospective China 223 116 63 (56–71) RT-PCR non-specific cancer patients with discontinous treatment
Lunski MJ [18] 2020 Retrospective USA 312 142 NA RT-PCR non-specific cancer patients with no treatment
Nie L [53] 2020 Retrospective China 45 31 66 (58–74) RT-PCR lung cancer cancer patients with no treatment
Larfors G [54] 2020 Retrospective Sweden NA NA NA RT-PCR non-specific cancer patients with no treatment
H€ollein A [55] 2020 Retrospective Germany 17 8 73 (27–82) RT-PCR non-specific cancer patients with no treatment
Garnett C [56] 2020 Retrospective UK 32 21 72.5 (46–96) RT-PCR hematological malignancies cancer patients with no treatment
Hanna GJ [57] 2020 Retrospective USA 32 20 70 (38–91) RT-PCR head and neck cancer cancer patients with no treatment
Lie’vre A [58] 2020 Retro-prospective France 1289 795 67 (19–100) RT-PCR solid tumor cancer patients with no treatment
Smith M [59] 2020 Retrospective USA 86 NA 69 (mean) RT-PCR solid tumor cancer patients with no treatment
Wu YG [60] 2020 Retrospective China 14 9 37 (14–68) RT-PCR hematological malignancies cancer patients with no treatment
Yang F [12] 2020 Retrospective China 52 28 63 (34–98) RT-PCR solid tumor cancer patients with no treatment
Author Number of the control Anti-tumor therapy Chemotherapy Immunotherapy Targeted therapy Endocrine therapy Surgery Radiotherapy Outcome Required mechanical ventilation Severe COVID-19 Death
Kuderer NM [6] 553 366 160 38 75 85 32 12 death 116 242 121
Lee LYW [19] 272 528 281 44 72 64 29 76 death NA 360 226
Zhang L [14] 22 6 3 1 2 NA NA 1 sever COVID-19 10 15 8
Stroppa EM [20] 13 12 8 4 NA NA NA NA death NA NA 9
Yang K [7] 128 54 31 4 12 NA 4 9 death 32 52 40
Zhang H [21] 70 37 NA 6 NA NA NA NA death NA 56 23
Robilotti EV [22] NA NA 191 31 NA NA 31 NA sever COVID-19 40 85 51
Yarza R [23] NA NA 36 8 7 10 NA NA sever COVID-19; death NA 24 16
Li Q [24] 43 16 12 NA 6 NA 1 1 death 27 35 16
Jee J [25] 43 170 102 18 49 NA NA NA sever COVID-19 NA 120 31
Sanchez-Pina JM [26] 15 24 4 NA 5 NA NA NA death NA 18 NA
Pinato DJ [15] 403 479 206 56 93 92 NA 33 sever COVID-19; death 97 565 299
Assaad S [27] 26 29 16 3 14 NA NA NA death NA NA 30
Garassino MC [28] 58 142 48 34 28 NA NA NA death 9 NA 66
Liang WH [29] 14 4 NA NA NA NA NA NA sever COVID-19 NA 9 NA
Ma J [30] 24 13 NA NA NA NA NA NA sever COVID-19 NA 20 5
Mehta V [11] NA NA 42 5 NA NA NA 49 death 45 NA 61
Yu J [31] 5 7 5 2 1 NA 1 4 sever COVID-19; death NA 3 3
Tian J [4] NA NA NA NA NA NA 119 NA sever COVID-19 NA 148 NA
Fox TA [32] NA NA 29 25 NA NA NA NA sever COVID-19; death NA 25 19
Booth S [33] 29 37 NA NA NA NA NA NA death NA NA 34
Cattaneo C [34] 43 59 20 28 NA NA NA NA death NA NA 40
Lara OD [35] NA NA NA NA NA NA NA NA death NA 20 NA
Liu C [36] 138 78 NA NA NA NA NA NA death NA NA 37
Luo J [37] 48 54 NA NA NA NA NA NA sever COVID-19; death 18 NA 25
Mato AR [38] 79 119 51 NA NA NA NA NA death 53 NA 66
Rogado J [39] 15 30 19 1 2 NA NA NA death NA 29 19
Russell B [40] 18 81 45 7 5 NA NA NA sever COVID-19; death NA 28 34
Scarfò L [41] 73 116 NA NA NA NA NA NA sever COVID-19; death NA 151 56
Vuagnat P [42] NA NA 29 NA 19 19 3 36 sever COVID-19 NA NA 4
Wang BO [43] 11 47 NA NA 28 NA NA NA death NA NA 14
Wang J [44] 188 95 46 NA 12 NA 23 NA sever COVID-19; death NA NA 50
Gonzalez-cao M [45] 12 38 NA 22 16 NA NA NA sever COVID-19; death NA 34 13
De Melo AC [46] 16 165 63 NA NA 20 12 10 death 34 NA 60
Albiges L [47] 61 117 66 19 30 16 NA NA sever COVID-19; death NA 47 31
Martínez-López J [48] NA NA 83 NA NA NA NA NA death 15 141 56
Martín-Moro F [49] NA 19 NA NA NA NA NA NA death 4 17 11
Lattenist R [50] 6 7 3 NA NA NA NA NA death NA NA 6
Nakamura S [51] 19 13 10 3 NA 4 13 NA death 3 NA 11
Rogiers A [52] NA NA 25 NA NA NA NA NA sever COVID-19; death NA 35 18
Glenthøj A [16] 10 9 NA NA NA NA NA NA sever COVID-19 NA 33 NA
Song C [17] 19 204 NA NA NA NA NA NA sever COVID-19 NA 159 NA
Lunski MJ [18] 256 56 12 4 9 44 5 2 death NA NA 66
Nie L [53] 34 11 4 4 NA NA 3 NA death 3 23 11
Larfors G [54] NA NA NA NA NA NA NA NA sever COVID-19; death NA NA NA
H€ollein A [55] 2 15 14 1 2 NA NA 1 death 3 NA 6
Garnett C [56] 10 22 NA NA NA NA NA NA death NA NA 18
Hanna GJ [57] 26 6 3 1 0 NA 4 1 death NA NA NA
Lie’vre A [58] NA NA 577 110 181 57 56 133 death 49 NA 370
Smith M [59] 47 39 NA NA NA NA NA NA sever COVID-19 NA 29 NA
Wu YG [60] NA NA 7 NA NA NA NA NA death NA NA 6
Yang F [12] NA NA 6 1 NA NA 2 NA sever COVID-19 NA 19 11
  1. Abbreviations: ICIs Immune checkpoint inhibitors, RT-PCR Reverse transcription-polymerase chain reaction, NA Not available, ICU Intensive Care Unit